시장보고서
상품코드
1101865

세계의 흡입 마취 시장 규모, 점유율, 업계 동향 : 약제별(Sevoflurane, Desflurane, Isoflurane, 기타), 용도별(유지, 도입), 지역별 전망과 예측(2022-2028년)

Global Inhalation Anesthesia Market Size, Share & Industry Trends Analysis Report By Drug (Sevoflurane, Desflurane, Isoflurane, and Others), By Application (Maintenance and Induction), By Regional Outlook and Forecast, 2022 - 2028

발행일: | 리서치사: KBV Research | 페이지 정보: 영문 142 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 흡입 마취 시장 규모는 예측기간 중 8.7%의 CAGR로 성장하여 2028년에는 19억 달러에 달할 것으로 예측됩니다.

수술 건수 증가, 신흥 국가에 의한 의료비 증가는 흡입 마취 시장 성장을 촉진하고 있습니다. 그러나 흡입 마취 과량 투여에 대한 약리학적 치료법이 없는 점이 시장 성장을 억제하고 있습니다.

세계의 흡입 마취(Inhalation Anesthesia) 시장에 대해 조사했으며, 시장 개요, 시장 분석, 기업 개요 등의 정보를 제공합니다.

목차

제1장 시장 범위와 조사 방법

제2장 시장 개요

  • 서론
  • 시장에 영향을 미치는 주요 요인

제3장 세계의 흡입 마취 시장 : 약제별

  • 세계의 Sevoflurane 시장 : 지역별
  • 세계의 Desflurane 시장 : 지역별
  • 세계의 Isoflurane 시장 : 지역별
  • 세계의 기타 시장 : 지역별

제4장 세계의 흡입 마취 시장 : 용도별

  • 세계의 마취 유지 시장 : 지역별
  • 세계의 마취 도입 시장 : 지역별

제5장 세계의 흡입 마취 시장 : 지역별

  • 북미의 흡입 마취 시장
  • 유럽의 흡입 마취 시장
  • 아시아태평양의 흡입 마취 시장
  • 라틴아메리카, 중동 및 아프리카의 흡입 마취 시장

제6장 기업 개요

  • Novartis AG
  • Piramal Enterprises Limited
  • Hikma Pharmaceuticals PLC
  • Fresenius SE & Co. KGaA
  • Baxter International, Inc.
  • AbbVie, Inc.
  • Halocarbon Products Corporation
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Lunan Pharmaceutical Group Co., Ltd.
  • Troikaa Pharmaceuticals Limited
KSM 22.07.22

The Global Inhalation Anesthesia Market size is expected to reach $1.9 billion by 2028, rising at a market growth of 8.7% CAGR during the forecast period.

In the operating room, inhalation anesthetics (nitrous oxide, halothane, isoflurane, desflurane, and sevoflurane, the most commonly used agents in practice today) are used to induce and maintain general anesthesia. Inhalation anesthetics are drugs used to give general anesthesia for surgery in the operating room.

According to NCBI data, approximately 310 million major procedures are performed worldwide each year, including about 40-50 million in the United States and 20 million in Europe. Following COVID-19, there has been a rise in the number of elective procedures, which has increased the demand for inhalation anesthetics even more. During the COVID-19 pandemic in 2020, the Centers for Medicare and Medicaid Services suggested that hospitals reduce, postpone, or cancel elective procedures, which resulted in a 48 percent decline in surgeries in the United States.

To provide general anesthesia, inhaled anesthetics are routinely employed. According to the National Institutes of Health, almost 60,000 people have surgery while under general anesthesia. Without general anesthesia, life-saving medical procedures such as open-heart surgery, brain surgery, or organ transplantation would not have been possible, driving up the demand for inhaled anesthetic medications.

Inhaled anesthetics help patients save money on their overall healthcare costs. Patients who have had surgery and are critically unwell are typically admitted to intensive care units (ICUs), which raise their healthcare costs due to the length of their hospital stays. Inhalation anesthetic aids surgeons in formulating dosages in order to avoid an extra hospital stay. This is not the case with intravenous anesthetic, which helps patients save money on their overall healthcare costs.

Covid-19 Impact

The COVID-19 pandemic put international hospitals and healthcare facilities under severe financial strain. For instance, the American Hospital Association forecasts that hospitals and healthcare systems in the United States will lose $202.6 billion in income, or $50.7 billion every month. Furthermore, providing an effective healthcare response to COVID-19 might cost low- and middle-income countries US$52 billion (equal to US$8.60 per person) every four weeks. In the context of the United States' greatest daily COVID-19 new cases, this load will have an impact on patient care, surgeries, and surgical results. World economic growth is expected to slow by over 8% this year, with poorer countries bearing the brunt of the damage, according to the World Bank.

Market Growth Factors

Growing Number of Surgeries

The inhalation anesthesia market is growing due to an increase in the number of emergency cases and road accidents, as well as an increase in the prevalence of various disorders such as cancer, respiratory diseases, and gastrointestinal disorders, as well as an increase in the number of surgical procedures and increased use of these in disease diagnosis. In addition, the global incidence of chronic diseases such as cancer, infectious diseases, and genetic abnormalities is increasing. Cancer is one of the main causes of morbidity and mortality worldwide, according to the WHO, with nearly 10 million deaths projected in 2020 alone, and this number is expected to rise over the next two decades. The majority of infections known to be caused by cancer strains occur in low- and middle-income nations.

Increase in Health Care Expenditure by Developing Countries

Health spending is expanding at a higher rate than the rest of the global economy, accounting for 10% of global GDP (GDP). The World Health Organization (WHO) has released a new report on global health expenditures that shows a rapidly rising trend, notably in low- and middle-income nations, where health spending is expanding at a rate of 6% annually on average, compared to 4% in high-income countries. Health spending is made up of government expenditure, out-of-pocket payments (people paying for their own care), and sources such as voluntary health insurance, employer-provided health programs, and activities by non-governmental organizations.

Market Restraining Factors

No Pharmacological Treatment for Inhaled Anesthetic Overdose

It's worth noting that there is no pharmacological treatment for inhaled anesthetic overdose. The primary treatment strategy in an overdose occurrence is supportive, with adequate ventilator settings and alveolar clearance. Inhaled agents can cause a variety of rare acute and chronic toxicities. Carbon monoxide poisoning (CO2), nephrotoxicity, and hepatotoxicity are examples of acute toxicities. Hematotoxicity, teratogenic consequences and carcinogenic toxicities are examples of chronic toxicities. Diffusion hypoxia can be caused by the dosage of Nitrous Oxide used in regular anesthesia. Nitrous oxide displaces air and oxygen from the alveoli when it exits the bloodstream and enters the lungs.

Drug Outlook

Based on Drug, the market is segmented into Sevoflurane, Desflurane, Isoflurane, and Others. The isoflurane segment procured a significant revenue share in the inhalation anesthesia market in 2021. Sevoflurane and desflurane are two to three times more expensive than isoflurane when fresh gas flow rates are taken into account. As a result of the availability of a cost-sensitive patient pool, anesthesiologists in underdeveloped nations choose isoflurane for inhalation general anesthesia.

Application Outlook

Based on Application, the market is segmented into Maintenance and Induction. The maintenance segment acquired the largest revenue share in the inhalation anesthesia market in 2021. Since inhaled anesthetics are widely preferred for anesthesia maintenance, the maintenance sector had the biggest market share in 2021. They provide more accurate control of the anesthetic state at a lower cost.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America acquired the largest revenue share in the anesthesia market in 2021. Due to an increase in the number of procedures conducted in the United States, North America dominated the market in 2021. Significant market income has also been obtained by key businesses in the country. In the United States, Piramal Enterprises Limited, a major participant in inhalation anesthesia, has the greatest market share of sevoflurane and isoflurane.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Piramal Enterprises Limited, Hikma Pharmaceuticals PLC, Fresenius SE & Co. KGaA, Baxter International, Inc., AbbVie, Inc., Halocarbon Products Corporation, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lunan Pharmaceutical Group Co., Ltd., and Troikaa Pharmaceuticals Limited.

Scope of the Study

Market Segments covered in the Report:

By Drug

  • Sevoflurane
  • Desflurane
  • Isoflurane
  • Others

By Application

  • Maintenance
  • Induction

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Novartis AG
  • Piramal Enterprises Limited
  • Hikma Pharmaceuticals PLC
  • Fresenius SE & Co. KGaA
  • Baxter International, Inc.
  • AbbVie, Inc.
  • Halocarbon Products Corporation
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Lunan Pharmaceutical Group Co., Ltd.
  • Troikaa Pharmaceuticals Limited

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Inhalation Anesthesia Market, by Drug
    • 1.4.2 Global Inhalation Anesthesia Market, by Application
    • 1.4.3 Global Inhalation Anesthesia Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Inhalation Anesthesia Market by Drug

  • 3.1 Global Sevoflurane Market by Region
  • 3.2 Global Desflurane Market by Region
  • 3.3 Global Isoflurane Market by Region
  • 3.4 Global Others Market by Region

Chapter 4. Global Inhalation Anesthesia Market by Application

  • 4.1 Global Maintenance Market by Region
  • 4.2 Global Induction Market by Region

Chapter 5. Global Inhalation Anesthesia Market by Region

  • 5.1 North America Inhalation Anesthesia Market
    • 5.1.1 North America Inhalation Anesthesia Market by Drug
      • 5.1.1.1 North America Sevoflurane Market by Country
      • 5.1.1.2 North America Desflurane Market by Country
      • 5.1.1.3 North America Isoflurane Market by Country
      • 5.1.1.4 North America Others Market by Country
    • 5.1.2 North America Inhalation Anesthesia Market by Application
      • 5.1.2.1 North America Maintenance Market by Country
      • 5.1.2.2 North America Induction Market by Country
    • 5.1.3 North America Inhalation Anesthesia Market by Country
      • 5.1.3.1 US Inhalation Anesthesia Market
        • 5.1.3.1.1 US Inhalation Anesthesia Market by Drug
        • 5.1.3.1.2 US Inhalation Anesthesia Market by Application
      • 5.1.3.2 Canada Inhalation Anesthesia Market
        • 5.1.3.2.1 Canada Inhalation Anesthesia Market by Drug
        • 5.1.3.2.2 Canada Inhalation Anesthesia Market by Application
      • 5.1.3.3 Mexico Inhalation Anesthesia Market
        • 5.1.3.3.1 Mexico Inhalation Anesthesia Market by Drug
        • 5.1.3.3.2 Mexico Inhalation Anesthesia Market by Application
      • 5.1.3.4 Rest of North America Inhalation Anesthesia Market
        • 5.1.3.4.1 Rest of North America Inhalation Anesthesia Market by Drug
        • 5.1.3.4.2 Rest of North America Inhalation Anesthesia Market by Application
  • 5.2 Europe Inhalation Anesthesia Market
    • 5.2.1 Europe Inhalation Anesthesia Market by Drug
      • 5.2.1.1 Europe Sevoflurane Market by Country
      • 5.2.1.2 Europe Desflurane Market by Country
      • 5.2.1.3 Europe Isoflurane Market by Country
      • 5.2.1.4 Europe Others Market by Country
    • 5.2.2 Europe Inhalation Anesthesia Market by Application
      • 5.2.2.1 Europe Maintenance Market by Country
      • 5.2.2.2 Europe Induction Market by Country
    • 5.2.3 Europe Inhalation Anesthesia Market by Country
      • 5.2.3.1 Germany Inhalation Anesthesia Market
        • 5.2.3.1.1 Germany Inhalation Anesthesia Market by Drug
        • 5.2.3.1.2 Germany Inhalation Anesthesia Market by Application
      • 5.2.3.2 UK Inhalation Anesthesia Market
        • 5.2.3.2.1 UK Inhalation Anesthesia Market by Drug
        • 5.2.3.2.2 UK Inhalation Anesthesia Market by Application
      • 5.2.3.3 France Inhalation Anesthesia Market
        • 5.2.3.3.1 France Inhalation Anesthesia Market by Drug
        • 5.2.3.3.2 France Inhalation Anesthesia Market by Application
      • 5.2.3.4 Russia Inhalation Anesthesia Market
        • 5.2.3.4.1 Russia Inhalation Anesthesia Market by Drug
        • 5.2.3.4.2 Russia Inhalation Anesthesia Market by Application
      • 5.2.3.5 Spain Inhalation Anesthesia Market
        • 5.2.3.5.1 Spain Inhalation Anesthesia Market by Drug
        • 5.2.3.5.2 Spain Inhalation Anesthesia Market by Application
      • 5.2.3.6 Italy Inhalation Anesthesia Market
        • 5.2.3.6.1 Italy Inhalation Anesthesia Market by Drug
        • 5.2.3.6.2 Italy Inhalation Anesthesia Market by Application
      • 5.2.3.7 Rest of Europe Inhalation Anesthesia Market
        • 5.2.3.7.1 Rest of Europe Inhalation Anesthesia Market by Drug
        • 5.2.3.7.2 Rest of Europe Inhalation Anesthesia Market by Application
  • 5.3 Asia Pacific Inhalation Anesthesia Market
    • 5.3.1 Asia Pacific Inhalation Anesthesia Market by Drug
      • 5.3.1.1 Asia Pacific Sevoflurane Market by Country
      • 5.3.1.2 Asia Pacific Desflurane Market by Country
      • 5.3.1.3 Asia Pacific Isoflurane Market by Country
      • 5.3.1.4 Asia Pacific Others Market by Country
    • 5.3.2 Asia Pacific Inhalation Anesthesia Market by Application
      • 5.3.2.1 Asia Pacific Maintenance Market by Country
      • 5.3.2.2 Asia Pacific Induction Market by Country
    • 5.3.3 Asia Pacific Inhalation Anesthesia Market by Country
      • 5.3.3.1 China Inhalation Anesthesia Market
        • 5.3.3.1.1 China Inhalation Anesthesia Market by Drug
        • 5.3.3.1.2 China Inhalation Anesthesia Market by Application
      • 5.3.3.2 Japan Inhalation Anesthesia Market
        • 5.3.3.2.1 Japan Inhalation Anesthesia Market by Drug
        • 5.3.3.2.2 Japan Inhalation Anesthesia Market by Application
      • 5.3.3.3 India Inhalation Anesthesia Market
        • 5.3.3.3.1 India Inhalation Anesthesia Market by Drug
        • 5.3.3.3.2 India Inhalation Anesthesia Market by Application
      • 5.3.3.4 South Korea Inhalation Anesthesia Market
        • 5.3.3.4.1 South Korea Inhalation Anesthesia Market by Drug
        • 5.3.3.4.2 South Korea Inhalation Anesthesia Market by Application
      • 5.3.3.5 Singapore Inhalation Anesthesia Market
        • 5.3.3.5.1 Singapore Inhalation Anesthesia Market by Drug
        • 5.3.3.5.2 Singapore Inhalation Anesthesia Market by Application
      • 5.3.3.6 Malaysia Inhalation Anesthesia Market
        • 5.3.3.6.1 Malaysia Inhalation Anesthesia Market by Drug
        • 5.3.3.6.2 Malaysia Inhalation Anesthesia Market by Application
      • 5.3.3.7 Rest of Asia Pacific Inhalation Anesthesia Market
        • 5.3.3.7.1 Rest of Asia Pacific Inhalation Anesthesia Market by Drug
        • 5.3.3.7.2 Rest of Asia Pacific Inhalation Anesthesia Market by Application
  • 5.4 LAMEA Inhalation Anesthesia Market
    • 5.4.1 LAMEA Inhalation Anesthesia Market by Drug
      • 5.4.1.1 LAMEA Sevoflurane Market by Country
      • 5.4.1.2 LAMEA Desflurane Market by Country
      • 5.4.1.3 LAMEA Isoflurane Market by Country
      • 5.4.1.4 LAMEA Others Market by Country
    • 5.4.2 LAMEA Inhalation Anesthesia Market by Application
      • 5.4.2.1 LAMEA Maintenance Market by Country
      • 5.4.2.2 LAMEA Induction Market by Country
    • 5.4.3 LAMEA Inhalation Anesthesia Market by Country
      • 5.4.3.1 Brazil Inhalation Anesthesia Market
        • 5.4.3.1.1 Brazil Inhalation Anesthesia Market by Drug
        • 5.4.3.1.2 Brazil Inhalation Anesthesia Market by Application
      • 5.4.3.2 Argentina Inhalation Anesthesia Market
        • 5.4.3.2.1 Argentina Inhalation Anesthesia Market by Drug
        • 5.4.3.2.2 Argentina Inhalation Anesthesia Market by Application
      • 5.4.3.3 UAE Inhalation Anesthesia Market
        • 5.4.3.3.1 UAE Inhalation Anesthesia Market by Drug
        • 5.4.3.3.2 UAE Inhalation Anesthesia Market by Application
      • 5.4.3.4 Saudi Arabia Inhalation Anesthesia Market
        • 5.4.3.4.1 Saudi Arabia Inhalation Anesthesia Market by Drug
        • 5.4.3.4.2 Saudi Arabia Inhalation Anesthesia Market by Application
      • 5.4.3.5 South Africa Inhalation Anesthesia Market
        • 5.4.3.5.1 South Africa Inhalation Anesthesia Market by Drug
        • 5.4.3.5.2 South Africa Inhalation Anesthesia Market by Application
      • 5.4.3.6 Nigeria Inhalation Anesthesia Market
        • 5.4.3.6.1 Nigeria Inhalation Anesthesia Market by Drug
        • 5.4.3.6.2 Nigeria Inhalation Anesthesia Market by Application
      • 5.4.3.7 Rest of LAMEA Inhalation Anesthesia Market
        • 5.4.3.7.1 Rest of LAMEA Inhalation Anesthesia Market by Drug
        • 5.4.3.7.2 Rest of LAMEA Inhalation Anesthesia Market by Application

Chapter 6. Company Profiles

  • 6.1 Novartis AG
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Segmental and Regional Analysis
    • 6.1.4 Research & Development Expense
    • 6.1.5 Recent strategies and developments:
      • 6.1.5.1 Product Launches and Product Expansions:
  • 6.2 Piramal Enterprises Limited
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Segmental and Regional Analysis
    • 6.2.4 Research & Development Expense
  • 6.3 Hikma Pharmaceuticals PLC
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Segmental and Regional Analysis
    • 6.3.4 Research & Development Expenses
  • 6.4 Fresenius SE & Co. KGaA
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Segmental and Regional Analysis
    • 6.4.4 Research & Development Expenses
  • 6.5 Baxter International, Inc.
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Regional Analysis
    • 6.5.4 Research & Development Expense
    • 6.5.5 Recent strategies and developments:
      • 6.5.5.1 Partnerships, Collaborations, and Agreements:
      • 6.5.5.2 Approvals and Trials:
  • 6.6 AbbVie, Inc.
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Regional Analysis
    • 6.6.4 Research & Development Expense
  • 6.7 Halocarbon Products Corporation
    • 6.7.1 Company Overview
  • 6.8 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    • 6.8.1 Company Overview
  • 6.9 Lunan Pharmaceutical Group Co., Ltd.
    • 6.9.1 Company Overview
  • 6.10. Troikaa Pharmaceuticals Limited
    • 6.10.1 Company Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제